Teva Pharmaceutical Industries (NYSE:TEVA) Raised to Hold at Zacks Research

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Wednesday, Zacks reports.

Several other brokerages also recently weighed in on TEVA. Leerink Partners lifted their target price on Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a research note on Thursday, November 12th. Argus increased their price target on Teva Pharmaceutical Industries from $42.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Oppenheimer increased their price target on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Fourteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.64.

View Our Latest Report on TEVA

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $38.53 on Wednesday. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. Teva Pharmaceutical Industries has a fifty-two week low of $24.01 and a fifty-two week high of $44.57. The firm has a 50-day simple moving average of $40.56 and a 200-day simple moving average of $35.22. The company has a market capitalization of $44.90 billion, a price-to-earnings ratio of 89.61, a price-to-earnings-growth ratio of 3.66 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.14. The firm had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.78 EPS. On average, equities research analysts anticipate that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 25,000 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $42.91, for a total value of $1,072,750.00. Following the sale, the executive vice president owned 55,755 shares of the company’s stock, valued at approximately $2,392,447.05. This represents a 30.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 715,945 shares of company stock worth $29,061,351 over the last ninety days. 0.54% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently made changes to their positions in the business. National Pension Service lifted its holdings in shares of Teva Pharmaceutical Industries by 4.9% in the second quarter. National Pension Service now owns 2,406,013 shares of the company’s stock valued at $81,516,000 after purchasing an additional 112,357 shares in the last quarter. Royal Bank of Canada grew its position in shares of Teva Pharmaceutical Industries by 11.2% in the first quarter. Royal Bank of Canada now owns 963,824 shares of the company’s stock valued at $29,030,000 after purchasing an additional 96,938 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Teva Pharmaceutical Industries by 1.3% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company’s stock valued at $1,561,120,000 after purchasing an additional 500,000 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Teva Pharmaceutical Industries by 5.8% during the 2nd quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock worth $259,899,000 after purchasing an additional 419,329 shares in the last quarter. Finally, Sei Investments Co. increased its stake in shares of Teva Pharmaceutical Industries by 22.5% during the 1st quarter. Sei Investments Co. now owns 1,182,751 shares of the company’s stock worth $35,624,000 after purchasing an additional 217,487 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

More Teva Pharmaceutical Industries News

These are some of the TEVA news items that stood out recently:

  • Positive Sentiment: Barclays raised its price target to $50 from $47 and maintained an Overweight rating. Argus also raised its target to $50 and reaffirmed a Buy rating, while HC Wainwright maintained its Buy rating. Barclays analyst action Argus forecast HC Wainwright rating
  • Neutral Sentiment: Teva said its R&D strategy, priorities and commitments remain unchanged, including its goal of $6–7 billion in innovative-medicines revenue by 2030. David Gardiner will lead the transition while the company searches for a permanent successor. Teva leadership announcement
  • Negative Sentiment: Executive Vice President of Global R&D and Chief Medical Officer Eric Hughes is leaving for an opportunity outside Teva. His departure may unsettle investors given the importance of R&D execution to the company’s growth strategy, despite his planned support during the transition. R&D leadership transition report

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Further Reading

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.